Medtronic Secures Category I CPT Code Approvals for Altaviva™ and Symplicity Spyral™ Systems

Medtronic (NYSE: MDT) this week announced it has received Category I CPT® code approvals for its Altaviva™ and Symplicity Spyral™ systems.

This approval, announced on October 1, 2026, reflects growing clinical evidence and physician adoption of these technologies addressing urge urinary incontinence and hypertension.

Category I CPT codes are central to billing and reimbursement in the U.S. healthcare system. These approvals are expected to streamline insurance claims and facilitate wider clinical adoption of the two systems, potentially supporting procedural volumes and revenue growth over time.

Why It Matters

Altaviva™, part of Medtronic’s neuromodulation portfolio, offers a therapy for urge urinary incontinence, while Symplicity Spyral™ targets hypertension through renal denervation. Both represent strategic, high-growth areas aligned with Medtronic’s innovation pipeline.

These reimbursements remove a key barrier to adoption—insurance coverage—placing the products in a stronger position to gain traction among healthcare providers.

Stock Context

As of market close October 9, 2026, Medtronic shares traded at $88.48, down 0.01% intraday. While the share movement was marginal, the CPT code approvals offer a clear pathway to improved procedural uptake and long-term performance support.

The news did not produce an immediate stock move, which is not unusual for reimbursement-related developments whose benefits may materialize over time as adoption grows.

What to Watch Next

Investors should monitor clinical adoption rates, payer coverage updates, and subsequent procedure volume growth for these systems. Additional catalysts could include real-world adoption metrics from key health systems or follow-on endorsements from clinical societies.

Further regulatory progress or expanded codes—for example, in related indications or geographies—could also enhance the commercial outlook for Medtronic’s neuromodulation and cardiovascular platforms.

In summary, the receipt of Category I CPT® codes for Altaviva™ and Symplicity Spyral™ systems represents a meaningful step toward improved reimbursement and clinical uptake, with potential long-term implications for Medtronic’s growth trajectory.